Structure of Lonidamine
CAS No.: 50264-69-2
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Lonidamine is an inactivator of hexokinase.
Synonyms: AF-1890; Diclondazolic Acid; Doridamina
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 50264-69-2 |
Formula : | C15H10Cl2N2O2 |
M.W : | 321.16 |
SMILES Code : | O=C(C1=NN(CC2=CC=C(Cl)C=C2Cl)C3=C1C=CC=C3)O |
Synonyms : |
AF-1890; Diclondazolic Acid; Doridamina
|
MDL No. : | MFCD00866285 |
InChI Key : | WDRYRZXSPDWGEB-UHFFFAOYSA-N |
Pubchem ID : | 39562 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
4T1 cells | 0.1 mg/mL | 12 hours | Evaluate the photothermal therapeutic effect of BTN@LND NPs on 4T1 cells, results showed that BTN@LND + L group caused over 95% cell death after 1064 nm laser irradiation | PMC11007887 |
LM3 cells | 15 µg/mL | 12 hours | To evaluate the inhibitory effect of LND on glycolysis, the results showed that LND significantly reduced extracellular lactate levels, indicating that LND effectively inhibited glycolysis. | PMC10724989 |
MDA-MB-231 cells | 40 μg/mL | 24 hours | To evaluate the apoptosis-inducing effect of LND-PLGA/TPS/DSSR NPs on MDA-MB-231 cells, the results showed that LND-PLGA/TPS/DSSR NPs significantly increased the proportion of early and late apoptotic cells. | PMC10378575 |
LM3 cells | 15 µg/mL | 24 hours | To evaluate the inhibitory effect of LND on HK activity, the results showed that LND significantly reduced intracellular HK levels, indicating a significant inhibitory effect of LND on HK activity. | PMC10724989 |
Bone marrow-derived macrophages (BMDMs) | 200 μM | 30 minutes | LND inhibited NLRP3 inflammasome activation, reducing caspase-1 and IL-1β secretion. | PMC9798610 |
J774A.1 cells | 200 μM | 30 minutes | LND inhibited NLRP3 inflammasome activation, reducing caspase-1 and IL-1β secretion. | PMC9798610 |
LM3 cells | 15 µg/mL | 4 hours | To evaluate the effect of LND on intracellular GSH levels, the results showed that LND significantly reduced intracellular GSH levels. | PMC10724989 |
HCT 116 | 50 μM | 48 h | Lonidamine potentiated the oncolytic effect and increased the infection rate of M1 virus. | PMC7607643 |
HCT-8 | 50 μM | 48 h | Lonidamine potentiated the oncolytic effect and increased the infection rate of M1 virus. | PMC7607643 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
BALB/c mice | 4T1 subcutaneous tumor model | Intravenous injection | 2.0 mg/mL | Single injection, laser irradiation after 24 hours | Evaluate the anti-tumor effect of BTN@LND NPs in the 4T1 subcutaneous tumor model, results showed that BTN@LND + L group significantly inhibited tumor growth with only a 1.9-fold increase in tumor volume after 1064 nm laser irradiation | PMC11007887 |
C57BL/6 mice | LPS-induced sepsis model | Intraperitoneal injection | 40 mg/kg and 60 mg/kg | Single injection | LND significantly alleviated the inflammatory response in the LPS-induced sepsis model, reducing serum levels of IL-1β and IL-18. | PMC9798610 |
BALB/c Nude mice | TNBC MDA-MB-231 xenograft model | Intravenous injection | 4 mg/kg | Every other day for 18 days | To evaluate the anti-tumor activity of LND-PLGA/TPS/DSSR NPs in the TNBC MDA-MB-231 xenograft model, the results showed that LND-PLGA/TPS/DSSR NPs significantly inhibited tumor growth and reduced the toxicity of LND. | PMC10378575 |
BALB/c Nude mice | LM3 subcutaneous xenograft tumor models | Tail vein injection | 15 µg/mL | Injected at days 1, 3 and 5, lasted for 18 days | To evaluate the effect of LND on tumor hypoxia, the results showed that LND significantly relieved tumor hypoxia. In addition, LND significantly reduced HSP90 expression in tumor tissues, enhancing the efficacy of photothermal therapy. | PMC10724989 |
BALB/c-nu/nu mice | HCT 116 tumor xenograft model | Intraperitoneal injection | 10 mg/kg | Once daily for 5 days | Lonidamine in combination with M1 virus significantly inhibited tumor growth without affecting mouse body weight. | PMC7607643 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00435448 | Benign Prostatic Hyperplasia|E... More >>nlarged Prostate Less << | PHASE3 | TERMINATED | 2025-12-06 | Vivantes Klinikum am Urban, Kl... More >>inik für Urologie, Berlin, 10967, Germany|ClinPharm International GmbH & Co KG--Chemnitz, Chemnitz, 09120, Germany|ClinPharm International GmbH & Co KG--Dresden, Dresden, 01067, Germany|niversit?tsklinikum Carl Gustav Carus, Klinik und Poliklinik für Urologie, Dresden, 01307, Germany|Gemeinschaftspraxis Jacobi - Hellmis, Duisburg, 47179, Germany|ClinPharm International GmbH & Co KG--Frankfurt/Main, Frankfurt, 60596, Germany|ClinPharm International GmbH & Co KG--Gorlitz, Gorlitz, 02826, Germany|Universit?tsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Urologie, Hamburg, 20246, Germany|Universit?tsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Urologie und Kinderurologie, Kiel, 24105, Germany|Universit?tsklinik K?ln, Klinik und Poliklinik für Urologie, K?ln, 50924, Germany|ClinPharm International GmbH & Co KG--Leipzig, Leipzig, 04229, Germany|ClinPharm International GmbH & Co KG--Magdeburg, Magdeburg, 39104, Germany|Urologische Universit?tsklinik, Klinikum Mannheim gGmbH, Fakult?t für Klinische Medizin Mannheim, Mannheim, 68135, Germany|Klinik für Urologie und Kinderurologie, Klinikum Marburg, Marburg, 35033, Germany|Klinikum der Universit?t München, Urologische Klinik und Poliklinik, München, 81377, Germany|Urologische Klinik und Poliklinik der Technischen Universit?t München, Klinikum Rechts der Isar, München, 81675, Germany|Urologische Klinik, Klinikum Landkreis Neumarkt i.d.Obf., Neumarkt, 92318, Germany|Klinik für Urologie, Eberhard-Karls-Universit?t Tübingen, Tubingen, 72076, Germany|Wuppertaler Gemeinschaftspraxis für Dermatologie, Gyn?kologie und Urologie, Wuppertal, 42103, Germany|Károlyi Sándor Hospital, Budapest, 1047, Hungary|Semmelweis University, Budapest, 1082, Hungary|F?városi ?nkormányzat Jahn Ferenc Dél-Pesti Kórház, Budapest, 1204, Hungary|Clinic of Urology, Debrecen, 4012, Hungary|Dombóvári Szt. Lukács Egészségügyi K?zhasznú, Dombóvár, 7200, Hungary|Petz Aladár County Hospital, Gyor, 9024, Hungary|Kaposi Mór County Hospital, Kaposvar, 7400, Hungary|Nagykanizsa Megyei Jogú Város Hospital, Nagykanizsa, 8800, Hungary|Gróf Esterházy Kórház, Papa, 8500, Hungary|Dr. Bugyi István Hospital, Szentes, 6600, Hungary|Saint Bobála Hospital, Tatabánya, 2800, Hungary|A.O. Policlinico di Bari, Clinica Urologica I, Bari, 70124, Italy|A.O. Policlinico di Bari, Clinica Urologica, Bari, 70124, Italy|Ospedale S.Annunziata, Unità Operativa di Urologia, Firenze, 50011, Italy|Università di Genova Ospedale S. Martino, Reparto Urologia, Genova, 16132, Italy|Ospedale S.Paolo, Cattedra di Urologia, Milano, 20142, Italy|Università Federico II, Clinica Urologica Edificio 5, Napoli, 80131, Italy|Azienda Ospedaliera S.Luigi di Orbassano, Reparto di urologia universitaria, Orbassano, 10043, Italy|Azienda Ospedaliera, Dipartimento di Urologia, Padova, 35128, Italy|A.O. Pliclinico Paolo Giaccone, U.O. Urologia con Litotrissia Extracorporea, Palermo, 90129, Italy|Azienda Ospedaliera Pisana, Dipartimento di Urologia 1, Pisa, 56126, Italy|Policlinico Sassarese, Istituto di Clinica Urologica, Sassari, 07100, Italy|Ospedale Maggiore S.Giovanni Battista, Istituto di Urologia, Torino, 10126, Italy|Ospedale S.Giovanni Bosco, Dipartimento di Urologia, Torino, 10154, Italy|Klinika Urologii AM w Bia?ymstoku, Bialystok, 15-276, Poland|Wojewódzki Szpital Specjalistyczny nr 4, Bytom, 41-902, Poland|Gabinet Urologiczny, Gdańsk, 80-210, Poland|Specjalistyczna Praktyka Lekarska, Katowice, 40-086, Poland|Szpital Specjalistyczny Oddzial Urologii, Koscierzyna, 83-400, Poland|"Specjalista" Spó?ka z o. o., Kutno, 99-300, Poland|Wojewódzki Szpital,Oddzia? i Poradnia Urologiczna, Legnica, 59-220, Poland|Szpital Im. Kardyna?a Stefana Wyszyńskiego, Oddzia? Urologii, Lublin, 20-718, Poland|Wojewódzki Szpital Specjalistyczny im. Janusza Korczaka, Oddzia? Urologii, Slupsk, 76-200, Poland|Katedra i Klinika Urologii Pomorskiej Akademii Medycznej, Szczecin, 70-111, Poland|Szpital Bielański, Oddzia? Urologii, Warszawa, 01-908, Poland|Szpital Specjalistyczny, Oddzia? Urologii, Wejherowo, 84-200, Poland|Katedra i Klinika Urologii AM we Wroc?awiu, Wroclaw, 50-043, Poland|Katedra i Klinika Urologii ?l?skiej Akademii Medycznej, Zabrze, 41-800, Poland|NZOZ Lekarze Urolodzy, Marek Rozniecki i Partnerzy, ?ask, 98-100, Poland Less << |
NCT00237536 | Benign Prostatic Hyperplasia | PHASE2 | TERMINATED | 2025-08-06 | Advanced Clinical Therapeutics... More >>, Tucson, Arizona, 85712, United States|Chris B. Threatt, MD Inc., Atherton, California, 94027, United States|Urological Sciences Research Foundation, Culver City, California, 90232, United States|Atlantic Urological Medical Group, Long Beach, California, 90806, United States|California Professional Research, Newport Beach, California, 92660, United States|San Diego Uro-Research, San Diego, California, 92103, United States|Stanford University Hospital, Stanford, California, 94305, United States|Urology Research Options, Aurora, Colorado, 80012, United States|Connecticut Clinical Research Center Urology Specialists, Waterbury, Connecticut, 06708, United States|South Florida Medical Research, Aventura, Florida, 33180, United States|Tampa Bay Medical Research, Clearwater, Florida, 33761, United States|Florida Healthcare Research, Ocala, Florida, 34474, United States|Midwest Prostate & Urology Health Center, Chicago, Illinois, 60640, United States|Specialty Care Research, Peoria, Illinois, 61614, United States|Northeast Indiana research, LLC, Fort Wayne, Indiana, 46825, United States|Metropolitan Urology, Jeffersonville, Indiana, 47130, United States|Werner, Murdock & Francis, PA, Urology Associates, Greenbelt, Maryland, 20770, United States|Sheldon J. Freedman, MD Ltd., Las Vegas, Nevada, 89109, United States|Delaware Valley Clinical Research, Cherry Hill, New Jersey, 08003, United States|Lawrenceville Urology, Lawrenceville, New Jersey, 08648, United States|Urology Healthcare Associates, Westampton, New Jersey, 08060, United States|Accumed Research Associates, Garden City, New York, 11530, United States|New York University School of Medicine, New York, New York, 10016, United States|Weill Medical College of Cornell University, New York, New York, 10021, United States|Radiant Research. Columbus, Columbus, Ohio, 43212, United States|Urological Associates of Lancaster, Lancaster, Pennsylvania, 17604, United States|State College Urologic Associates, State College, Pennsylvania, 16801, United States|University Urological Research Institute, Providence, Rhode Island, 02904, United States|Radiant Research, Greer, Greer, South Carolina, 29651, United States|UT Southwestern Medical Center at Dallas, Dept of Urology, Dallas, Texas, 75390, United States|Accelovance, Houston, Texas, 77024, United States|Baylor College of Medicine, Scott Department of Urology, Houston, Texas, 77030, United States|Urology San Antonio Research, San Antonio, Texas, 78229, United States|Integrity Medical Research, LLC, Mountlake Terrace, Washington, 98043, United States Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
3.11mL 0.62mL 0.31mL |
15.57mL 3.11mL 1.56mL |
31.14mL 6.23mL 3.11mL |
Tags: Lonidamine | AF-1890 | Diclondazolic Acid | DICA | AF1890 | AF 1890 | Hexokinase | Mitochondrial Metabolism | Apoptosis | Parasite | Mitochondrial | lung fibrosis | pulmonary fibrosis | hexokinase inhibitor | mitochondrial pyruvate carrier inhibitor | aerobic glycolysis | cancer metabolism | pulmonary fibrosis | mitochondrial metabolism | inflammation | 50264-69-2
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL